GT201400306A - Formas de administración farmacéuticas que comprenden 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida - Google Patents
Formas de administración farmacéuticas que comprenden 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamidaInfo
- Publication number
- GT201400306A GT201400306A GT201400306A GT201400306A GT201400306A GT 201400306 A GT201400306 A GT 201400306A GT 201400306 A GT201400306 A GT 201400306A GT 201400306 A GT201400306 A GT 201400306A GT 201400306 A GT201400306 A GT 201400306A
- Authority
- GT
- Guatemala
- Prior art keywords
- oxo
- thiofencarboxamide
- morfolinil
- oxazolidin
- chlorine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A FORMAS DE ADMINISTRACIÓN FARMACÉUTICAS ADMINISTRABLES POR VÍA ORAL SÓLIDAS QUE COMPRENDEN 5-CLORO-N-({(5S)-2-OXO-3-[4-(3-OXO-4-MORFOLINIL)FENIL]-1,3-OXAZOLIDIN-5-IL}METIL)-2-TIOFENCARBOXAMIDA (RIVAROXABÁN, COMPUESTO ACTIVO (I)), CARACTERIZADAS PORQUE SE LIBERA RÁPIDAMENTE UNA CANTIDAD PARCIAL DEL COMPUESTO ACTIVO (I) Y SE LIBERA UNA CANTIDAD PARCIAL DE UNA FORMA CONTROLADA (MODIFICADA, RETARDADA, POSPUESTA), Y A PROCEDIMIENTOS PARA SU PREPARACIÓN, A SU USO COMO MEDICAMENTOS Y A SU USO PARA LA PROFILAXIS, PROFILAXIS SECUNDARIA O TRATAMIENTO DE TRASTORNOS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12174797 | 2012-07-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT201400306A true GT201400306A (es) | 2015-08-25 |
Family
ID=48782297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT201400306A GT201400306A (es) | 2012-07-03 | 2014-12-30 | Formas de administración farmacéuticas que comprenden 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US20150125527A1 (es) |
| EP (1) | EP2869814B1 (es) |
| JP (1) | JP6166781B2 (es) |
| KR (1) | KR20150027284A (es) |
| CN (1) | CN104582684A (es) |
| AP (1) | AP3756A (es) |
| AR (1) | AR091621A1 (es) |
| AU (1) | AU2013286068A1 (es) |
| BR (1) | BR112015000043A2 (es) |
| CA (1) | CA2878123A1 (es) |
| CL (1) | CL2015000002A1 (es) |
| CO (1) | CO7240379A2 (es) |
| CR (1) | CR20150001A (es) |
| CU (1) | CU20140152A7 (es) |
| DO (1) | DOP2015000001A (es) |
| EA (1) | EA025016B1 (es) |
| EC (1) | ECSP14033581A (es) |
| ES (1) | ES2574627T3 (es) |
| GT (1) | GT201400306A (es) |
| HK (1) | HK1209635A1 (es) |
| IL (1) | IL236455A0 (es) |
| IN (1) | IN2014DN11066A (es) |
| MA (1) | MA37721B1 (es) |
| MX (1) | MX2015000053A (es) |
| NZ (1) | NZ703733A (es) |
| PE (1) | PE20150189A1 (es) |
| PH (1) | PH12014502833A1 (es) |
| SG (1) | SG11201408420YA (es) |
| TN (1) | TN2014000541A1 (es) |
| TW (1) | TW201414508A (es) |
| UY (1) | UY34856A (es) |
| WO (1) | WO2014005934A1 (es) |
| ZA (1) | ZA201500759B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102008059206A1 (de) * | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
| PT3377176T (pt) * | 2016-02-23 | 2022-01-13 | Morgandane Scient Llc | Método de tratamento de pacientes aos quais foram coadministrados rivaroxabano e verapamil |
| CN107823166A (zh) * | 2016-09-21 | 2018-03-23 | 齐鲁制药有限公司 | 一种利伐沙班片的制备方法 |
| AU2019311234A1 (en) * | 2018-07-24 | 2021-02-04 | Bayer Aktiengesellschaft | Pharmaceutical dosage form which can be administered orally and has modified release |
| WO2020020790A1 (de) * | 2018-07-24 | 2020-01-30 | Bayer Aktiengesellschaft | Oral applizierbare pharmazeutische darreichungsform mit modifizierter freisetzung |
| US10722486B2 (en) | 2018-08-13 | 2020-07-28 | Morgandane Scientific, LLC | Method of treating patients with a factor Xa inhibitor, aspirin, and verapamil |
| JP7641098B2 (ja) * | 2019-08-30 | 2025-03-06 | 日本ジェネリック株式会社 | リバーロキサバン含有錠剤 |
| JP7465157B2 (ja) * | 2020-06-15 | 2024-04-10 | 沢井製薬株式会社 | リバーロキサバン含有口腔内崩壊錠の製造方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
| NZ206600A (en) | 1983-05-11 | 1987-01-23 | Alza Corp | Osmotic drug delivery device |
| US5160744A (en) | 1991-06-27 | 1992-11-03 | Alza Corporation | Verapmil therapy |
| US6919373B1 (en) * | 1996-11-12 | 2005-07-19 | Alza Corporation | Methods and devices for providing prolonged drug therapy |
| DE19747261A1 (de) | 1997-10-25 | 1999-04-29 | Bayer Ag | Osmotisches Arzneimittelfreisetzungssystem |
| HK1046638B (zh) * | 1998-06-03 | 2006-02-24 | 阿尔扎有限公司 | 提供药物长效治疗的方法和装置 |
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| US8092831B2 (en) * | 2002-11-08 | 2012-01-10 | Andrx Pharmaceuticals, Llc | Antihistamine and decongestant system |
| KR20090080143A (ko) * | 2003-09-02 | 2009-07-23 | 화이자 프로덕츠 인크. | 지프라시돈의 지속 방출형 투여 형태 |
| DE10355461A1 (de) | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
| DE102004062475A1 (de) * | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
| JP2011527297A (ja) * | 2008-07-08 | 2011-10-27 | ラーツイオフアルム・ゲー・エム・ベー・ハー | ５−クロロ−ｎ−（｛（５ｓ）−２−オキソ−３−［４−（３−オキソ−４−モルホリニル）−フェニル］−１，３−オキサゾリジン−５−イル｝−メチル）−２−チオフェンカルボキサミドを含む医薬組成物 |
| GB201003734D0 (en) * | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Delayed prolonged drug delivery |
| WO2011163206A2 (en) * | 2010-06-22 | 2011-12-29 | Twi Pharmaceuticals, Inc. | Controlled release compositions with reduced food effect |
-
2013
- 2013-06-11 UY UY34856A patent/UY34856A/es not_active Application Discontinuation
- 2013-06-28 US US14/412,487 patent/US20150125527A1/en not_active Abandoned
- 2013-06-28 HK HK15110431.9A patent/HK1209635A1/xx unknown
- 2013-06-28 SG SG11201408420YA patent/SG11201408420YA/en unknown
- 2013-06-28 ES ES13735235.7T patent/ES2574627T3/es active Active
- 2013-06-28 NZ NZ703733A patent/NZ703733A/en not_active IP Right Cessation
- 2013-06-28 AU AU2013286068A patent/AU2013286068A1/en not_active Abandoned
- 2013-06-28 PE PE2014002579A patent/PE20150189A1/es not_active Application Discontinuation
- 2013-06-28 JP JP2015519105A patent/JP6166781B2/ja not_active Expired - Fee Related
- 2013-06-28 KR KR20157002492A patent/KR20150027284A/ko not_active Withdrawn
- 2013-06-28 CA CA2878123A patent/CA2878123A1/en not_active Abandoned
- 2013-06-28 AR ARP130102318 patent/AR091621A1/es unknown
- 2013-06-28 US US13/930,094 patent/US20140010876A1/en not_active Abandoned
- 2013-06-28 CN CN201380035605.8A patent/CN104582684A/zh active Pending
- 2013-06-28 AP AP2015008208A patent/AP3756A/en active
- 2013-06-28 EA EA201590142A patent/EA025016B1/ru not_active IP Right Cessation
- 2013-06-28 EP EP13735235.7A patent/EP2869814B1/de active Active
- 2013-06-28 MX MX2015000053A patent/MX2015000053A/es unknown
- 2013-06-28 WO PCT/EP2013/063590 patent/WO2014005934A1/de not_active Ceased
- 2013-06-28 IN IN11066DEN2014 patent/IN2014DN11066A/en unknown
- 2013-06-28 BR BR112015000043A patent/BR112015000043A2/pt active Search and Examination
- 2013-07-02 TW TW102123589A patent/TW201414508A/zh unknown
-
2014
- 2014-12-19 PH PH12014502833A patent/PH12014502833A1/en unknown
- 2014-12-25 IL IL236455A patent/IL236455A0/en unknown
- 2014-12-30 EC ECIEPI201433581A patent/ECSP14033581A/es unknown
- 2014-12-30 TN TN2014000541A patent/TN2014000541A1/fr unknown
- 2014-12-30 GT GT201400306A patent/GT201400306A/es unknown
- 2014-12-30 CU CU2014000152A patent/CU20140152A7/es unknown
- 2014-12-31 MA MA37721A patent/MA37721B1/fr unknown
- 2014-12-31 CO CO14287291A patent/CO7240379A2/es unknown
-
2015
- 2015-01-02 DO DO2015000001A patent/DOP2015000001A/es unknown
- 2015-01-02 CL CL2015000002A patent/CL2015000002A1/es unknown
- 2015-01-05 CR CR20150001A patent/CR20150001A/es unknown
- 2015-02-02 ZA ZA2015/00759A patent/ZA201500759B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP14033581A (es) | Formas de administración farmacéuticas que comprenden 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida | |
| CU23808B7 (es) | Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo | |
| IL231358A (en) | Topical veterinary compositions comprising an isoxazoline active agent for treating or preventing parasitic infection or infestation | |
| EA201492290A1 (ru) | Составы и способы для вагинальной доставки антипрогестинов | |
| BR112013025969A2 (pt) | forma de dose unitária para administração oral | |
| EA201500742A1 (ru) | Защищенные от нецелевого использования фармацевтические композиции | |
| CL2016002132A1 (es) | Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo. | |
| BR112015009228A8 (pt) | Formulação farmacêutica líquida estéril e forma de dosagem intraocular oftálmica líquida estéril para injeção | |
| UA116999C2 (uk) | Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить | |
| MX390461B (es) | Metodos y composiciones particularmente para el tratamiento del trastorno por deficit de atencion | |
| EA201501164A1 (ru) | Твердая фармацевтическая лекарственная форма | |
| MX2016013245A (es) | Regimen de dosificacion de liberacion inmediata de moduladores s1p. | |
| CO7380758A2 (es) | Derivados de la 2-(morfolin-4-il)-3-(1-amino-3-trifluorometil-piridin-4-il)-5-(oxazol-3-il-2-ona)-pirimidina, activos como inhibidores pi3k mtor, composiciones farmacéuticas del mismo, y sus métodos de fabricación | |
| BR112014009580A2 (pt) | composição farmacêutica de omeprazol | |
| ES2429422R1 (es) | Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH | |
| MX2017004772A (es) | Composiciones y métodos para la administración fisiológica utilizando cannabidiol. | |
| ES2421956A1 (es) | Nueva forma cristalina de sulfato de sitagliptina | |
| HUE050945T2 (hu) | Gyógyszerforma hatóanyagok nyújtott felszabadítására | |
| BR112014009760A2 (pt) | análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo | |
| MX2019004736A (es) | Mini-tabletas de melatonina y metodos de fabricacion de las mismas. | |
| UY34154A (es) | Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel. | |
| AR093252A1 (es) | Composicion farmaceutica oral utilizada como antiparasitaria y antidiarreica y procesos para prepararla | |
| UY35004A (es) | Forma amorfa estabilizada de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen | |
| PE20170201A1 (es) | Formas de dosificacion farmaceutica | |
| PT2988782T (pt) | Formas de dosagem para administração oral de substâncias ativas |